media – Page 8 – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

Nanchang International Medical Equipment Exhibition

Organiser: Nanchang Municipal People’s Government, Chinese Research Hospital Association Time：August 21–23, 2025 address：No. 1315 Huaiyushan Avenue, Honggutan New District, Nanchang City Exhibition hall：Nanchang Greenland International Expo Center Product range: Cardio-cerebrovascular Monitoring Equipment: EEG machines, EMG machines, ECG machines, evoked potential devices, remote monitoring systems, HOLTER monitors, defibrillator monitors, exercise treadmill ECG systems, ambulatory blood pressure monitors, oximeters, and auxiliary diagnostic devices. Medical Materials and Supplies: Various medical consumables, enamel and glassware, dressing rubber products, disposable items, reagents, clinical laboratory equipment, and blood transfusion supplies. Clinical Laboratory Equipment: Medical incubators, centrifuges, microscopes, pre-analytical processing equipment, and body fluid handling devices. Biochemical Analysis Instruments: Automatic biochemical analyzers, hematology analyzers, hemodialysis machines, blood gas analyzers, microbiology analyzers, urinalysis analyzers, flow cytometers, electrolyte analyzers, ELISA readers, chromatographs, PCR machines, DNA synthesizers, laboratory instruments, apparatus, and supplies. Blood Transfusion Equipment: Blood testing devices, refrigeration equipment, blood collection and supply instruments, blood bank equipment, blood bank ...
- Source: drugdu
- 86
- July 15, 2025
CStone Pharmaceuticals and Istituto Gentili Enter into European Commercialization Collaboration

Recently , CStone Pharmaceuticals announced that it has reached an exclusive strategic cooperation with Istituto Gentili (hereinafter referred to as Gentili) on the commercialization of Sugemalimab in Western Europe and the United Kingdom. Gentili has obtained the exclusive commercialization rights of Sugemalimab in 23 countries, and CStone Pharmaceuticals will receive a payment of up to US$192.5 million, including an initial payment, registration and sales milestone payments, and a revenue share of nearly 50% of the net sales of Sugemalimab in the authorized area. This cooperation shows that CStone Pharmaceuticals’ products have been recognized in the international market, which will help enhance its influence in the field of global cancer treatment. In the long run, this cooperation will enhance investors’ confidence in the company’s future growth and lay the foundation for the company to further expand its overseas market. https://www.nbd.com.cn/articles/2025-07-08/3936641.html
- Source: drugdu
- 43
- July 14, 2025
The rise of PD-1/VEGF triple antibodies

With Kangfang Biopharma’s successful challenge to PD-1 monoclonal antibody with Ivoside, tumor immunotherapy (IO) has rapidly evolved to the 2.0 era. PD-(L)1/VEGF bispecific antibodies have been snapped up by MNCs, and PD-(L)1/VEGF trispecific antibodies have gradually become a research and development trend, indicating that tumor treatment is accelerating towards multi-target synergy. Recently, CStone Pharmaceuticals announced the latest clinical progress of its independently developed potential first-in-class/best-in-class CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody). The drug has balanced monovalent PD-1 and CTLA-4 binding arms and bivalent VEGFA binding arms, which can produce strong multi-target synergistic effects and preferentially target tumor tissues to reduce systemic toxicity. The global multi-center Phase I/II clinical study of CS2009 is actively recruiting patients in Australia and China, and plans to expand to the United States for Phase II enrollment. Currently, the trial enrollment is very rapid, and the number of patients is expected to exceed 100 by the end of ...
- Source: drugdu
- 41
- July 14, 2025
The leading domestic pharmaceutical company for general cell therapy of Parkinson’s disease has obtained tens of millions of yuan in market-based financing within a few months!

According to industrial and commercial information, in May 2025, Roche Biopharmaceuticals (Suzhou/Shanghai) Co., Ltd. (Roche Accelerator Member) has completed a new round of market-oriented financing . The new financing came from Jianfa Emerging Investment, Suzhou Angel Fund, Xinxi Capital, and Qisheng Capital. Just a few months ago, in October 2024, Shize Bio officially announced the completion of more than 100 million yuan in B1 round of market-oriented financing : the B1 round of financing was led by Tailong/Taikun Capital, co-invested by Qisheng Capital and Tianhui Capital, and additional investments from old shareholders such as Frees Capital, Qiming Venture Partners, Lilly Asia Fund, and Sequoia China. The B1 round of financing will be used to improve Shize Bio’s clinical-grade iPS-derived cell drug pipeline for the treatment of neurological diseases, further conduct clinical research, and promote multiple registered clinical trials. During the overall downturn of the pharmaceutical industry from 2022 to 2025, ...
- Source: drugdu
- 40
- July 14, 2025
Henlius HLX43 has been approved by multiple countries to conduct an international multi-center Phase II clinical trial in NSCLC, leading the global development of PD-L1 ADC

Recently, Henlius has made another important progress in the global development of its innovative programmed death-ligand 1 (PD-L1) antibody-drug conjugate (ADC) injection HLX43. The product has been approved by the China National Medical Products Administration (NMPA), the U.S. Food and Drug Administration (FDA), the Australian Therapeutic Goods Administration (TGA) and the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) to conduct an international multicenter Phase II clinical study for advanced non-small cell lung cancer (NSCLC), and the first subject has been dosed in China. No similar ADC product targeting PD-L1 has been approved for marketing in the world, and HLX43 is the world’s first PD-L1 ADC to enter Phase II clinical trials. According to the latest data from GLOBOCAN, lung cancer is the cancer with the highest morbidity and mortality in the world. In 2022, there will be more than 2.48 million new cases of lung cancer worldwide, accounting for 12.4% ...
- Source: drugdu
- 74
- July 14, 2025
A subsidiary of United Pharmaceuticals received FDA approval for clinical trials of innovative drugs

On July 10, United Pharmaceutical (03933) issued an announcement, announcing that its wholly-owned subsidiary United Biotech received approval from the U.S. FDA on July 4, 2025 to register its Class 1 innovative drugUBT37034 injection is used in clinical trials for the indication of overweight or obesity. The drug was developed by Federal Biotechnology and has independent intellectual property rights.It is a new type of peptide receptor agonist that can reduce body weight by selectively acting on neuropeptide Y2 receptors. The announcement mentioned that preclinical animal model studies of UBT37034 showed that it can significantly reduce body weight when used in combination with GLP-1 analogs. The company said it will continue to focus on new product research and development, enhance its competitiveness and creativity in the biopharmaceutical industry, and is expected to create greater benefits for the company and its shareholders. https://finance.eastmoney.com/a/202507103453263675.html
- Source: drugdu
- 49
- July 14, 2025
SINOPHARM New Drug Application Accepted

On July 10, SINOPHARM (01177) announced that the Group’s independently developed CDK2/4/6 inhibitor Cumocillin Capsules “TQB3616” combined with Fulvestrant Injection for previously untreated HR-positive, HER2-negative (HR+/HER2-) locally advanced or metastatic breast cancer has been submitted to the Center for Drug Evaluation of the China National Medical Products Administration for new indications for marketing approval and has been accepted. The approval of the first-line indication application further confirms the broad potential of this combination therapy in different treatment stages of advanced breast cancer. In addition, the new drug application for Cumosili submitted by the Group in July 2024 has also been accepted by the CDE for use in combination with Fulvestrant for the treatment of HR+/HER2- locally advanced or metastatic breast cancer that has been previously treated with endocrine therapy. The announcement mentioned that breast cancer is one of the most common malignant tumors in women, of which HR+/HER2- breast cancer ...
- Source: drugdu
- 55
- July 14, 2025
【EXPERT Q&A】How to standardize drug information?

Drugdu.com expert’s response: Standardizing drug information is a critical step in enhancing medical data quality, facilitating information sharing, and ensuring medication safety. Below are the specific methods and steps to achieve drug information standardization: I. Clarify Standardization Objectives and Scope Define Core Objectives Improve Data Consistency: Ensure consistent naming and dosage representations of the same drug across different systems. Support Cross-System Interoperability: Enable data exchange among hospitals, pharmacies, and regulatory agencies. Ensure Medication Safety: Avoid medication errors caused by information confusion. Meet Regulatory Requirements: Comply with national drug coding standards, electronic health record (EHR) specifications, etc. II. Define Standardization Scope Basic Information: Drug names, ingredients, dosage forms, specifications, manufacturers, etc. Clinical Information: Indications, usage and dosage, contraindications, adverse reactions, etc. Administrative Information: Drug codes, classifications, prices, inventory, etc. Research Information: Pharmacokinetic parameters, clinical trial data, etc. Establish a Unified Drug Information Standard System Adopt International/National Standards Drug Coding: Utilize internationally ...
- Source: drugdu
- 90
- July 14, 2025
【EXPERT Q&A】What are the standards and procedures for compliance review?

Drugdu.com expert’s response: I. Standards for Compliance Review The standards for compliance review serve as benchmarks to ensure that the actions of enterprises or organizations are lawful and compliant, primarily covering the following three aspects: Legal and Regulatory Requirements National Laws and Regulations: These include the Constitution, laws, administrative regulations, departmental rules, and local regulations, such as the Company Law, Labor Law, and Cybersecurity Law. International Treaties and Regulatory Provisions: For foreign-involved enterprises, compliance with the laws and regulations of the host country where investments are made, international conventions (e.g., GDPR), and bilateral treaty agreements is required. Industry Regulatory Requirements: Examples include capital adequacy ratios and risk management regulations in the financial sector, as well as medical device approval processes in the healthcare industry. Industry Standards and Best Practices Industry Codes: Examples include the Basel Accords in the financial sector and ISO 13485, the quality management system standard for medical devices. Social Responsibility ...
- Source: drugdu
- 96
- July 11, 2025
The application for the marketing approval of the innovative drug in the field of autoimmune diseases jointly developed with Connect Biopharmaceuticals has been accepted

Simcere Pharma (02096) announced on the evening of July 8 that the company and Hong Kong Connect BiopharmaceuticalsInnovative drugs developed by pharmaceutical companiesThe New Drug Application (NDA) for Ledeqibaimab has been accepted by the China National Medical Products Administration (NMPA) and is intended for the treatment of atopic dermatitis in adults and adolescents. Ledeqibaimab is a fully human monoclonal antibody targeting IL-4Rα (a common subunit of IL-4 and IL-13 receptors). By blocking the functions of IL-4 and IL-13, the drug can effectively inhibit the Th2-type inflammatory pathway, thus providing a possible treatment for Th2-related inflammatory diseases such as atopic dermatitis and asthma. According to reports, Connect Biopharma is a global clinical-stage biopharmaceutical company focused on the development of innovative therapies for inflammatory diseases. In addition to atopic dermatitis, the company is conducting global studies on Ledeqibaimab for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) ...
- Source: drugdu
- 52
- July 10, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.